Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
The company expects that this development could improve the strength of its application to the FDA for new drug approval
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
LG Chem is making progress in the development of the world's first oral treatment for rare forms of obesity.
GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
Lucid-MS is a new drug candidate for the treatment of multiple sclerosis
‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis,
New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease
Subscribe To Our Newsletter & Stay Updated
